Private equity funds managed by Blackstone have entered into a definitive agreement to acquire contract research organization (CRO) Nucleus Network from Australian private equity firm Crescent Capital.
The value of the transaction was not disclosed. For its part, Melbourne-based Crescent Capital acquired Nucleus Network in 2018 from the Baker Heart and Diabetes Institute, an independent medical research institute, also for an undisclosed amount.
Nucleus Network conducts outsourced Phase I clinical trials -- the earliest-stage trials in humans -- for clients in the pharmaceutical and biotechnology industries. The company bills itself as Australia's largest CRO . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.